Navigation Links
Matrix Genomics, Elizabeth Corder, PhD - Gene Variation in the LRRK2 Gene and High Risk for Parkinson's Disease
Date:6/8/2009

Researchers at the National Institute on Aging, University College London, and Matrix Genomics, Inc. have identified a concise genetic signature found among a third of Parkinson's disease (PD) patients - but at very low frequency in the general population. The signature is found in the LRRK2 gene located on chromosome 12. The work was led by Elizabeth Corder, PhD, Scientific director at Matrix Genomics, Inc.

(PRWEB) June 5, 2009 -- Researchers at the National Institute on Aging, University College London, and Matrix Genomics, Inc. have identified a concise genetic signature found among a third of Parkinson's disease (PD) patients - but at very low frequency in the general population. The signature is found in the LRRK2 gene located on chromosome 12. The work was led by Elizabeth H. Corder, PhD, Scientific Director at Matrix Genomics.

Parkinson's disease is the second most common neurodegenerative disorder in the Western world, and a major cause of disability and distress among older Americans. Family studies have long indicated that Parkinson's is a genetic disorder when certain mutations are inherited. However, specific genetic factors relevant to the general population have been elusive.

The PD gene is called leucine risk repeat kinase 2 (LRRK2), which encodes a protein called dardarin, derived from the Basque word dardara, meaning tremor. Mutations in LRRK2 are a common cause of familial Parkinson's disease.

This study published in the Annals of Human Genetics describes a combination of four gene variants found in a third of Parkinson's cases, but infrequent in the population. Thus the presence or absence of this signature can be used as a genetic test for Parkinson's disease (Patent pending).

Earlier work had identified each of the four variants as being associated with PD risk, but did not combine the information to make a specific risk signature.

Genetic testing using this approach is expected to identify a third of persons at very high risk. It will not identify other genetic factors or level of risk due to environmental exposures, such as pesticides, and lifestyle. Thus the absence of this risk signature does not guarantee low risk.

This finding helps us understand what causes PD and could lead to new and more effective avenues for prevention and treatment. The advance is expected to identify individuals at greatest risk for PD before symptoms arise, when therapies and lifestyle changes might be most effective in slowing disease progression.

In 1993, Dr. Corder was the lead author on the Science article that described how risk for Alzheimer's disease multiplied according to the number of copies of the apolipoprotein E allele 4 inherited from parents. This finding has been replicated in hundreds of studies and remains the one established genetic risk factor for Alzheimer's disease, and the prototype for investigating common gene variants for common disorders.

###

Read the full story at http://www.prweb.com/releases/2009/06/prweb2496714.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
2. BioNanomatrix Announces Issuance of Key Nanofluidics Patent Enabling Single Molecule Whole Genome Analysis
3. BioNanomatrix Receives New NCI Grant to Support Development of Chip-Based Nanofluidics Systems for Cell Fractionation
4. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
5. TEI Biosciences Launches SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction
6. Collagen Matrix, Inc. Launches OssiMend(TM) Bone Graft Matrix for Orthopedic and Spine Applications
7. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
8. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
9. Organogenesis, Inc. Announces Acquisition of NanoMatrix, Inc.
10. Engineers make first active matrix display using nanowires
11. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , ... March 21, 2017 , ... The Conference Forum ... (CMO Summit) to be held on May 10-11, 2017, at the Colonnade Hotel in ... specifically for Chief Medical Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical ...
(Date:3/22/2017)... ... March 22, 2017 , ... March 22, 2017...Council for ... another green revolution, one that utilizes technological innovation in smart, sustainable ways. Humans depend ... life such as aesthetics and environmental stability. This paper is the first in a ...
(Date:3/22/2017)... SAN FRANCISCO , March 22, 2017 /PRNewswire/ ... the fastest growing genetic information companies, today announced ... the diagnosis of Spinal Muscular Atrophy (SMA) ... the leading lethal genetic disorders among infants as ... disease in childhood. The new test, announced during ...
(Date:3/20/2017)... Diego, CA (PRWEB) , ... March 20, 2017 ... ... novel therapies for gastrointestinal (GI) disorders, today announced that it has entered into ... (NRG-4) for therapies in inflammatory bowel disease including Necrotizing Enterocolitis (rare orphan disease) ...
Breaking Biology Technology:
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global ... reach $11.4 billion by 2021, growing at a compound annual ... - An overview of the global markets for synthetic biology. ... estimates for 2016, and projections of compound annual growth rates ...
(Date:2/7/2017)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the latest release ... flexible and award winning eClinical solution, is now available ... is a proven Software-as-a-Service (SaaS) clinical research technology platform ... also delivers an entire suite of eClinical tools to ...
Breaking Biology News(10 mins):